Janeo

Sitagliptin, the active ingredient in Janeo, is a DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving blood‑glucose control. GNH USA supplies Janeo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation. - Type 2 diabetes mellitus: improves glycemic control when combined with diet and exercise. - As monotherapy: lowers HbA1c levels in patients inadequately controlled by lifestyle alone. - As add‑on therapy: enhances glucose control when used with other antidiabetic agents such as metformin or sulfonylureas.

Sitagliptin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory infection: cough, sore throat, or congestion. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Dizziness: occasional light‑headed sensation. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with vomiting. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Renal impairment worsening: increased serum creatinine or reduced clearance.

Before initiating therapy, clinicians should consider several safety aspects. - Renal function assessment: adjust dose in patients with reduced creatinine clearance. - Pancreatitis monitoring: educate patients to report persistent abdominal pain. - Concomitant hypoglycemic agents: monitor for additive glucose‑lowering effect. - Elderly patients: start at lower dose and observe tolerance. - Hepatic impairment: use with caution and evaluate liver enzymes. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise sitagliptin plasma levels. - Other DPP‑4 inhibitors: combined use offers no added benefit and raises adverse‑event risk.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may affect renal clearance of sitagliptin. - Rifampin: may reduce sitagliptin exposure, requiring efficacy monitoring.